Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early treatment and dose optimisation BENEFIT and BEYOND.

Hans-Peter Hartung1

  • 1Department of Neurology, Heinrich-Heine-Universität, Moorenstrasse 5, 40225 Düsseldorf, Germany Hans-Peter.Hartung@uni-duesseldorf.de

Journal of Neurology
|September 20, 2005
PubMed
Summary

Early interferon beta (IFNbeta) treatment and higher doses may improve multiple sclerosis (MS) outcomes. Studies like BENEFIT and BEYOND investigate optimal early treatment strategies for relapsing-remitting MS (RRMS).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.

Multiple sclerosis (Houndmills, Basingstoke, England)·2020
Same author

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.

EBioMedicine·2020
Same author

[Ocrelizumab for treatment of multiple sclerosis].

Der Nervenarzt·2020
Same author

Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS.

Neurology(R) neuroimmunology & neuroinflammation·2020
Same author

Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.

EBioMedicine·2020
Same author

COVID-19 and management of neuroimmunological disorders.

Nature reviews. Neurology·2020

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Interferon beta (IFNbeta) remains a cornerstone in multiple sclerosis (MS) treatment, with evolving paradigms focusing on early intervention and optimized dosing.
  • Irreversible neurological damage, including axonal loss, occurs early in relapsing-remitting MS (RRMS), underscoring the need for timely and effective therapies.

Purpose of the Study:

  • To evaluate the long-term clinical and MRI outcomes of early, high-dose, and frequent administration of IFNbeta-1b in newly diagnosed RRMS patients.
  • To investigate the efficacy of a higher dose of IFNbeta-1b (500 microg) compared to the standard dose (250 microg) in treatment-naïve RRMS patients.
  • To compare the efficacy of high-dose IFNbeta-1b against glatiramer acetate in treatment-naïve RRMS patients.

Main Methods:

  • The BENEFIT study assesses early intervention with high-dose IFNbeta-1b (250 microg every other day) in early RRMS.

Related Experiment Videos

  • The BEYOND study compares IFNbeta-1b 500 microg every other day against 250 microg every other day and glatiramer acetate 20mg daily in treatment-naïve RRMS patients.
  • Evidence from previous studies (PRISMS, INCOMIN, EVIDENCE) supports a dose-response relationship for IFNbeta in RRMS treatment.

    • Main Results:

    • Previous studies indicate a dose-response relationship for IFNbeta in RRMS, with higher doses showing greater efficacy.
    • A pilot study suggested that increasing IFNbeta-1b to 500 microg resulted in a more pronounced biological effect than the standard 250 microg dose.
    • The BENEFIT and BEYOND studies are designed to provide further data on long-term outcomes and comparative efficacy.

    Conclusions:

    • Early initiation of IFNbeta treatment in RRMS is supported by evidence of early irreversible pathology.
    • Optimizing IFNbeta dosage and frequency may enhance therapeutic effects and influence long-term disease progression.
    • Ongoing studies are crucial for establishing the most effective early treatment strategies for MS, potentially involving higher doses or novel comparators.